Lifeboat Foundation

Researchers are edging closer to a therapy for Angelman syndrome that involves injecting molecules that can edit genes into the fetal brain. They have already succeeded in mice and say the approach could eventually treat people with the syndrome.

The work is of high interest because a similar strategy could also work for other genetic conditions linked to autism.

But the prospect of injecting molecules into fetal brains poses ethical questions, experts caution.